Over the past few months, MIT has been working closely with a Russian distributor to cover its marketing and sales in Russia. The newly signed distributor agreement and initial order worth approximately half-a-million dollars in Med-Jet products for the mesotherapy market is in progress.
Mr Karim Menassa was in Moscow for a sales and marketing kick off meeting to launch the Med-Jet products into the lucrative cosmetic market. The meeting was organized by MIT's Russian distributor and held at a prestigious Moscow hotel in the presence of over 300 specialists, in addition to Canadian dignitaries and local and international media.
MIT is delighted to have received the official certification to sell MED-JET® products to a very important market, said MIT President and CEO, Mr Karim Menassa. This new distributor will help MIT Canada achieve its business plan, which forecasts multi-million dollars of sales in different niche markets worldwide within the next 3 to 5 years.
Dr. Francis Bellido, Vice-President and Chief Strategy Officer of MIT Canada believes that the access to the fast growing Russian cosmetic market is a tremendous achievement and will serve to open future markets around the world to MIT's unique and effective products and technologies.
Medical International Technology Inc. is proud to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet® and Agro-Jet® needle-free injection system.
About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.